Chemical Engineering @ChemengFiles.Com

Kiadis Pharma has announced that Andrea Velardi, MD, Professor of Clinical Immunology at the University of Perugia (Italy) and Kiadis Pharma will continue their collaboration in ATIR (TM), a product in clinical development to enable the use of a poorly matched donor in a bone marrow transplantation by preventing graft versus host disease (GvHD) in patients with leukemia in the final phase. Under the agreement, Professor Velardi continue development of the selective reduction of donor T cells alorreactivas matched using the wrong product Kiadis Pharma, ATIR (TM). Kiadis Pharma is preparing for a pivotal multicenter study on ATIR (TM) to begin early in 2009 and Professor Velardi participate in this next study.

A team with the participation of the Consejo Superior de Investigaciones Científicas (CSIC), has identified in animal models of the molecular causes of genetic predisposition to colon cancer.

The work, published in Genome Research, clarifies why smad7, gene marker of the risk of disease, contributes to the development of the disease and opens the door to the design of potential therapeutic strategies.

23andMe, Inc. and mondoBIOTECH AG have announced at the World Economic Forum deDavos (Switzerland), which are collaborating on the progress of research in rare diseases. This announcement represents a return of the companies at the World Economic Forum, where both received recognition as Technology Pioneers in 2008.